Day: February 27, 2025

MINNEAPOLIS, Feb. 27, 2025 (GLOBE NEWSWIRE) — Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles today announced results for its fourth quarter and full-year ended December 31, 2024.Fourth Quarter 2024 Summary Net Sales Decreased 5.9%Comparable Store Sales Decreased 5.8% Gross Margin of 64.2%Net Loss of $0.6 Million and Adjusted EBITDA of $3.4 MillionNet Loss per Share of $0.01No Debt Outstanding and $21.0 million of Cash at Year-End Full-Year 2024 Summary Net Sales Decreased 8.0%Comparable Store Sales Decreased 7.8% Gross Margin of 65.7%Net Income of $2.3 Million and Adjusted EBITDA of $22.6 MillionDiluted Earnings per Share of $0.05 Management Commentary – Cabell Lolmaugh, CEO “While the challenges facing the home improvement sector continued...

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Perimeter Medical Imaging AI, Inc. (TSX-V: PINK; OTCQX: PYNKF), a commercial stage medical technology company, has qualified to trade on the OTCQX® Best Market. Perimeter Medical Imaging AI, Inc. upgraded to OTCQX from the Pink® market. Perimeter Medical Imaging AI, Inc. begins trading today on OTCQX under the symbol “PYNKF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market...

WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the TD Cowen 45th Annual Health Care Conference being held at the Marriott Copley Place in Boston, MA on Wednesday, March 5, 2025 at 1:10 p.m. Eastern Time. A webcast of the presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event. About TScan Therapeutics, Inc. TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered...

BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 6, 2025, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under “Events and Presentations” in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants...

VAL-D’OR, Quebec, Feb. 27, 2025 (GLOBE NEWSWIRE) — Cartier Resources Inc. (″Cartier″ or the ″Company″) (TSXV: ECR; FSE:6CA) is pleased to announce it has launched the Artificial Intelligence (″AI″) Targeting Program on the Cadillac Project, in the Val-d’Or mining camp (Quebec). The program incorporates VRIFY’s cutting-edge AI-Assisted Mineral Discovery Platform. VRIFY uses advanced AI and proprietary algorithms to generate a prospectivity score — known as a VRIFY Prospectivity Score (VPS) — that identifies areas for potential of gold mineralization. The VPS and models generated through the AI-Assisted Mineral Discovery Platform incorporate probabilistic values, which help to determine the accuracy and reliability of the predictions. Philippe Cloutier, President & CEO, stated: ″We are very excited to partner with the VRIFY...

TORONTO, Feb. 27, 2025 (GLOBE NEWSWIRE) — Nobel Resources Corp. (TSX – V: NBLC) (the “Company” or “Nobel”) is pleased to announce that its common shares (the “Nobel Shares”) will recommence trading on the TSX Venture Exchange (“TSXV”) on March 3, 2025. Trading of the Nobel Shares on the TSXV has been halted since the Company announced it had entered into option agreements to acquire a Chilean copper portfolio in Antofagasta Region, Chile (the “Transaction”). Please refer to the Company’s press release dated January 6, 2025 for further details regarding the Transaction. The Company has submitted a draft NI 43-101 technical report for the Cuprita project, the cornerstone property in the Transaction, to the TSXV and is working to satisfy the TSXV’s conditions to close the Transaction. About Nobel Nobel Resources is a Canadian resource...

– Company Expands Exports to Overseas Medical Cannabis Market with Top-Selling Pink Kush Cultivar – VANCOUVER, British Columbia, Feb. 27, 2025 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today announced its first shipment to New Zealand through its wholly-owned subsidiary Pure Sunfarms. The shipment features Pink Kush, the top-selling dried flower strain over the past four years1 in Canada, the largest federally legal market in the world. Pink Kush, along with a portfolio of our globally recognized strains, will be distributed in New Zealand by Medleaf Therapeutics (“Medleaf”) under its the ‘Bloom’ brand, created specifically for products from Pure Sunfarms. Medleaf is an established New Zealand-based medical cannabis company with a comprehensive distribution network, collaborating...

The POET Optical Interposer™ earns its 4th prestigious honor in less than a year TORONTO, Feb. 27, 2025 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company“) (TSX Venture: PTK; NASDAQ: POET), a leader in the design and implementation of highly integrated optical engines and light sources for Artificial Intelligence networks, today announced that it was the recipient of another prestigious award. Lightwave+BTR Innovation Reviews, a recognized authority in the optoelectronics industry, named POET as an Elite Score recipient for its 2025 awards. The publication, which recognizes excellence in a product or technology applicable to optical networks, singled out the POET Optical Interposer™ for the honor. A panel of judges, comprised of experts from the optical communications and broadband...

– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA. Phase 1/2 enrollment expected to begin 1H 2025 – – Clinical collaboration with Eli Lilly to evaluate TNG456 in combination with CDK4/6 inhibitor Verzenio® (abemaciclib) established –  – Data update from ongoing TNG462 monotherapy trial expected in 2025 with focus on pancreatic and lung cancer – – Cash position of $258 million as of December 31, 2024, with cash runway expected to fund operations into 3Q 2026 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines,...